Quectel Achieves ISO 26262 ASIL B Automotive Functional Safety Certifications as Well as ISO/SAE 21434 Automotive Cybersecurity Management System Certification
2.11.2023 13:00:00 EET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, is delighted to announce it has been awarded the ISO 26262:2018 Functional Safety Process Certificate by Bureau Veritas (BV), a trusted and industry-recognized third-party certification body. This milestone confirms that Quectel has successfully established a complete set of robust functional safety management process system in accordance with ISO 26262 standards, providing continuous support for the design and manufacturing of products that adhere to international safety standards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231102951870/en/
Quectel achieves ISO 26262 ASIL B automotive functional safety certifications as well as ISO/SAE 21434 Automotive Cybersecurity Management System certification (Photo: Business Wire)
In addition, Quectel's LG69T (AB) automotive-grade GNSS module has received certification for meeting the stringent requirements of ISO 26262 ASIL B metrics, which underscores the LG69T (AB)'s ability to fulfill functional safety requirements, positioning it as a dependable solution for global automotive manufacturers and Tier-one suppliers.
Norbert Muhrer, President and CSO, Quectel Wireless Solutions, commented, "Securing ISO 26262 certifications marks a significant milestone in Quectel's commitment to delivering top-tier products and services to the global automotive market. With these certifications, our LG69T (AB) module, and forthcoming products, will play a pivotal role in advancing vehicle safety and the evolution of autonomous driving. Moving forward, we remain dedicated to creating more automotive-grade products that meet safety standards, contributing to the ongoing development of the intelligent driving industry."
As driving technology progresses to more advanced levels of automation, the number of electronic and electrical systems within vehicles continues to grow. The complexity of software and hardware systems presents additional challenges in functional safety technologies. Selecting components compliant with functional safety standards can assist automotive manufacturers and Tier-one suppliers in improving their product development processes, ultimately ensuring vehicle safety.
Quectel’s LG69T (AB) is an automotive-grade high-precision GNSS positioning module based on the STMicroelectronics Teseo APP platform. When combined with multiple positioning technologies such as Real-Time Kinematic (RTK) and Dead Reckoning (DR), this dual-frequency module can achieve centimeter-level positioning accuracy, nanosecond-level real-time response, and time and position sharing between vehicles.
Moreover, the LG69T (AB) features over 40 safety mechanisms encompassing temperature detection, tracking channel checks, signal quality monitoring, voltage monitoring, antenna monitoring, and more, ensuring continuous monitoring of the module's health status. Additionally, its high flexibility and configurability allow customization to meet the functional safety requirements of a wide range of application scenarios, according to customer needs.
In addition to obtaining ISO 26262 functional safety process certification, Quectel has earned other crucial certifications, including ISO/SAE 21434 Automotive Cybersecurity Management System certification which indicates the company’s organizational and engineering processes for cybersecurity are compliant with international standards, as well as ISO 27001 Product Information Security Management System certification, ASPICE CL2, CMMI Level 3, and IATF 16949:2016 Automotive Quality Management System certification. These certifications underscore Quectel's focus in providing high-quality, secure, and compliant automotive products and solutions to global partners in the automotive industry.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231102951870/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom